ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 143 filers reported holding ASCENDIS PHARMA A/S in Q1 2019. The put-call ratio across all filers is 0.49 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,041 | +4.9% | 481 | 0.0% | 0.01% | +20.0% |
| Q2 2023 | $42,929 | -16.8% | 481 | 0.0% | 0.01% | -28.6% |
| Q1 2023 | $51,573 | -12.2% | 481 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $58,745 | +19.9% | 481 | 0.0% | 0.01% | -12.5% |
| Q3 2022 | $49,000 | -12.5% | 481 | 0.0% | 0.01% | +14.3% |
| Q1 2022 | $56,000 | -13.8% | 481 | 0.0% | 0.01% | -12.5% |
| Q4 2021 | $65,000 | -15.6% | 481 | 0.0% | 0.01% | -11.1% |
| Q3 2021 | $77,000 | -38.9% | 481 | -49.9% | 0.01% | -47.1% |
| Q2 2021 | $126,000 | +1.6% | 961 | 0.0% | 0.02% | -22.7% |
| Q1 2021 | $124,000 | -12.7% | 961 | 0.0% | 0.02% | -37.1% |
| Q2 2020 | $142,000 | +31.5% | 961 | 0.0% | 0.04% | +16.7% |
| Q1 2020 | $108,000 | -1.8% | 961 | 0.0% | 0.03% | +3.4% |
| Q2 2019 | $110,000 | -2.7% | 961 | 0.0% | 0.03% | -6.5% |
| Q1 2019 | $113,000 | – | 961 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |